Subacute leukencephalopathy after low‐dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism

Tobias Strunk, Stefan Gottschalk, Wolfgang Goepel, Peter Bucsky, Christian Schultz

Medical and Pediatric Oncology · 2002 · 23 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

Methotrexate (MTX) is an essential chemotherapeutic agent for the treatment of neoplastic diseases. It has substantially contributed to the decrease of central nervous system (CNS) and testicular relapses in childhood acute lymphoblastic leukemia (ALL) and thus to the remarkably improved prognosis of this disease. However, intensive MTX-treatment bears considerable risk of acute and delayed toxicity, for example, mucositis, myelosuppression, renal dysfunction, and CNS toxicity. CNS abnormalities occur in a substantial number of patient's either on nuclear magnetic resonance (NMR) imaging alone or with clinical manifestations. These mainly comprise aseptic meningitis, transverse myelopathy, stroke-like syndrome, and acute or chronic encephalopathy Our experience with an adolescent who developed subacute leukencephalopathy after initial intrathecal MTX administration for ALL is instructive.

References

6